Atropine 0.05% Slows Myopia Progression in Children with Structural Eye Changes Revealed by OCTA

Atropine at 0.05% shows structural eye changes tied to slower myopia in children

A six‑month analysis nested within a randomized trial in China reports that nightly 0.05% atropine was associated with minimal refractive change and near‑stable axial length in school‑age children, alongside measurable remodeling of both the choroid and retina captured by swept‑source OCT angiography (SS‑OCTA). The findings reinforce short‑term effectiveness and point to imaging biomarkers that health systems could standardize as outcome measures in pediatric myopia programs.

What the imaging signals suggest about mechanism

The choroid is increasingly recognized as an active regulator of eye growth. In this cohort, 0.05% atropine was linked with macular CT and CVV expansion without a proportional change in CVI, a pattern consistent with simultaneous enlargement of vascular and stromal compartments rather than a shift in their ratio. This echoes emerging evidence that choroidal thickening under low‑dose atropine, including at 0.01%, can track with slower myopia progression in children and may serve as an early biomarker of treatment response.

Layer‑specific retinal thickening-RNFL, GCL+IPL, and ORL-tracked with slower axial elongation, aligning with longer‑term trials in which higher low‑dose concentrations (notably 0.05%) produced stronger control of SE progression and AL growth than 0.01%. A five‑year extension of this line of research also indicates durable control with continued or resumed 0.05% therapy (LAMP program). Together, the structural signals lend biological plausibility to dose‑response findings and give clinicians measurable tissue‑level changes to watch in the first treatment year.

Operational takeaways for clinics and programs

• Outcome tracking
  • Standardize SE and AL as core endpoints; add SS‑OCTA‑derived CT and CVV as exploratory biomarkers where imaging capacity exists.
  • Capture regional data (ETDRS quadrants; peripapillary ring) to detect spatially patterned responses that may forecast longer‑term benefit.
• Risk-benefit framing
  • Short‑term imaging changes coincided with clinically meaningful slowing of axial growth over 6 months, supporting continued follow‑up rather than early discontinuation when symptoms such as mild photophobia or near blur arise.
  • Retinal vessel density changes were subtle and inconsistent between groups, underscoring structure‑first effects within this timeframe and suggesting that perfusion metrics may be more useful as safety surveillance than as primary efficacy readouts.
• Equity and access
  • Programs serving younger children or those unable to handle contacts now have a spectacle‑based option with U.S. market authorization for progression control, allowing schools, health systems, and employer plans to consider device‑based pathways that do not depend on daily eyedrop adherence.
  • In regions relying on compounded low‑dose atropine, variability in formulation and labeling has been documented, reinforcing the need for rigorous sourcing and pharmacy quality assurance at the institutional level and for payers to recognize quality‑assured compounding as a distinct cost category.

United States regulatory landscape and coverage considerations

The U.S. regulatory position shapes how aggressively health systems can scale pediatric myopia control. Under the medical‑device framework of the U.S. Food and Drug Administration (FDA), products with explicit indications to slow myopia progression can be promoted and reimbursed differently from off‑label pharmaceutical use, a distinction that is now central to benefit‑design and procurement decisions.

Interpreting dose: evidence remains strongest for 0.05% in progression control

• Across multiple randomized trials, a concentration-response pattern is consistently observed over 1-2 years, with 0.05% showing larger effects on SE and AL than 0.01%. The new six‑month structural data are directionally consistent with those longer‑term functional results.
• Long‑term follow‑up indicates that stopping therapy can accelerate progression and that resuming 0.05% restores effect, an operational reality for multi‑year programs that must plan for adherence gaps, family moves, and transitions between providers.
• Findings with 0.01% are heterogeneous across settings; a U.S. multicenter trial reported no advantage over placebo at two years, while other studies report benefits over longer periods. For policymakers and clinical leaders, this heterogeneity argues for population‑specific evaluation rather than assuming a universal “low‑dose” standard.

System capacity, procurement, and data standards

• Workforce and equipment
  • Scaling SS‑OCTA for pediatric imaging requires technician training, motion‑artifact mitigation, and consistent segmentation review, which may need to be centralized in tertiary centers or shared‑service hubs.
  • Programs should plan for annual AL measurement capacity and age‑appropriate cycloplegic refraction protocols, embedding these into routine pediatric eye‑care pathways rather than ad‑hoc specialist visits.
• Procurement and quality oversight
  • Where compounded atropine is used, institutional buyers can prefer 503B outsourcing facilities or implement audits against stability and labeling benchmarks to reduce lot‑to‑lot variability, and should map these choices to internal risk‑management and pharmacy‑and‑therapeutics committee oversight.
• Coverage and affordability
  • Myopia control services are variably covered under vision benefits rather than medical insurance. Payers are more likely to recognize device‑based interventions with explicit FDA authorization; compounded pharmaceuticals may face greater variability in reimbursement and in cost‑sharing for families.
• Data standards
  • Programs can harmonize reporting on SE, AL, CT, and CVV, and stratify outcomes by macular quadrant and peripapillary sectors to support cross‑site comparisons and registries. Over time, this could inform guideline bodies and national screening recommendations.

Caveats in the new analysis

• The six‑month window limits inference about durability, inter‑dose comparisons beyond 0.05%, and rebound after cessation or tapering.
• The observational design of this secondary analysis cannot establish causality between structural change and slowed axial growth, and residual confounding-such as near‑work behavior or outdoor time-cannot be fully excluded.
• Outer retinal circulation was not assessed, possibly underestimating vascular effects and leaving open questions about microvascular safety in higher‑risk children.

Why this matters for public health planning

With pediatric myopia prevalence rising and high myopia linked to later‑life retinal disease and glaucoma risk, scalable interventions that slow axial elongation are increasingly a systems‑level priority. The present findings support the use of standardized imaging and biometric endpoints in clinic networks and trials, strengthen the case for dose‑optimized atropine protocols where used off‑label, and clarify how FDA‑authorized devices can be integrated to broaden access in younger or contact lens‑ineligible children.

For health ministries, school‑based vision programs, and large insurers, the emerging structural biomarkers around 0.05% atropine offer a way to monitor impact within three to six months rather than waiting years for refractive outcomes alone. As regulators such as the U.S. Food and Drug Administration refine pathways for pediatric myopia devices and drugs, that evidence base will shape reimbursement rules, equity initiatives, and cross‑border procurement strategies in what is rapidly becoming one of the most consequential pediatric eye‑health challenges worldwide.